- Home
- EQ vs FTHM Comparison
EQ vs FTHM Comparison
Compare EQ & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- FTHM
- Stock Information
- Founded
- EQ 2017
- FTHM 2010
- Country
- EQ United States
- FTHM United States
- Employees
- EQ N/A
- FTHM N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- FTHM Real Estate
- Sector
- EQ Health Care
- FTHM Finance
- Exchange
- EQ Nasdaq
- FTHM Nasdaq
- Market Cap
- EQ 31.1M
- FTHM 27.1M
- IPO Year
- EQ 2018
- FTHM 2020
- Fundamental
- Price
- EQ $0.88
- FTHM $1.15
- Analyst Decision
- EQ Buy
- FTHM Strong Buy
- Analyst Count
- EQ 2
- FTHM 4
- Target Price
- EQ $5.00
- FTHM $4.25
- AVG Volume (30 Days)
- EQ 2.2M
- FTHM 85.8K
- Earning Date
- EQ 03-24-2025
- FTHM 03-13-2025
- Dividend Yield
- EQ N/A
- FTHM N/A
- EPS Growth
- EQ N/A
- FTHM N/A
- EPS
- EQ N/A
- FTHM N/A
- Revenue
- EQ $45,914,000.00
- FTHM $317,515,000.00
- Revenue This Year
- EQ $4.77
- FTHM N/A
- Revenue Next Year
- EQ N/A
- FTHM $25.84
- P/E Ratio
- EQ N/A
- FTHM N/A
- Revenue Growth
- EQ 7.70
- FTHM N/A
- 52 Week Low
- EQ $0.49
- FTHM $1.12
- 52 Week High
- EQ $3.25
- FTHM $3.37
- Technical
- Relative Strength Index (RSI)
- EQ 58.42
- FTHM 35.56
- Support Level
- EQ $0.85
- FTHM $1.12
- Resistance Level
- EQ $0.98
- FTHM $1.24
- Average True Range (ATR)
- EQ 0.10
- FTHM 0.09
- MACD
- EQ 0.01
- FTHM 0.01
- Stochastic Oscillator
- EQ 62.50
- FTHM 14.29
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title.